The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...

Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...

Chronic kidney disease is a common complication for people living ... participants for an average of about 3½ years. The new ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

in adults with type 2 diabetes and chronic kidney disease. Ozempic is already widely used and was first FDA-approved in 2017 to treat type 2 diabetes. The medication — taken weekly by injection ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

Both type 1 and type 2 diabetes can cause kidney disease, the agency said ... according to the CDC. The FDA has approved Ozempic for type 2 diabetes, but it’s also known for its use off-label ...

The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, ...